Phytocomponents screening for oncoprotector development

Cover Page

Cite item

Full Text

Abstract

Background. Medicinal plants have a high chemopreventive potential in oncology. The structural diversity of plant biologically active substances: phenolic compounds (simple phenols, flavonoids, phenolic acids, tannins, etc.), terpenoids (mono-, diterpenoids, triterpene saponins, etc.), essential oils, for example, results in a wide range of antitumor activity. Complex herbal preparations are more effective and safe due to their multi-target effects on various regulatory mechanisms in combination with relatively low toxicity. The development of effective natural pharmaceutical compositions based on the structural diversity of biologically active substances seems relevant.

Aim. Number plant extracts antiproliferative effect against CaOv human ovarian adenocarcinoma cells investigation and potential phytocomponents selection for the novel antitumor pharmaceutical composition development.

Materials and methods. CaOv human ovarian adenocarcinoma cell line was used as a test model. The antiproliferative effect of plant extracts was measured by the radiometric method based on the 3H-thymidine incorporation into CaOv cells DNA. Half maximal inhibitory concentration (IC50) was calculated using probit analysis. The selection of vegetable oil as an optimal extraction agent was carried out on C57BL/6 male mice based on the wound healing effect.

Results. The antiproliferative activity of 27 medical plant extracts was studied. The 14 most effective ones in these conditions were selected based on the IC50. Linseed oil was chosen as an optimal extraction agent considered the wound-healing effect of individual vegetable oils (linseed, sunflower, corn), as well as the corresponding oil extracts of the phytocomposition.

Conclusion. The selected phytocomponents can be used as a foundation for an optimal compound development of a new pharmaceutical composition aimed at chemoprevention in cancer care. The choice of linseed vegetable oil as an experimental phytocomposition extractant is justified.

About the authors

O. A. Bocharova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-6365-2888

Olga A. Bocharova.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

A. A. Aksyonov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-6052-2132

Andrey A. Aksyonov.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

R. V. Karpova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: planta39@rambler.ru
ORCID iD: 0000-0003-4893-1472

Regina V. Karpova.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

E. V. Bocharov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-2342-9881

Evgeny V. Bocharov.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

N. N. Kasatkina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-4735-977X

Natalia N. Kasatkina.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

I. V. Kazeev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-6100-3470

Ilya V. Kazeev.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

M. V. Utkina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0009-0009-0483-5332

Marina V. Utkina.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

V. G. Kucheryanu

Institute of General Pathology and Pathophysiology

ORCID iD: 0000-0002-5071-3581

Valerian G. Kucheryanu.

8 Baltiyskaya St., Moscow 125315

Russian Federation

V. S. Kosorukov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-8462-2178

Vyacheslav S. Kosorukov.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

I. S. Stilidi

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-0493-1166

Ivan S. Stilidi.

24 Kashirskoe Shosse, Moscow 115522

Russian Federation

References

  1. Kubczak M., Szustka A., Rogalińska M. Molecular targets of natural compound with anticancer properties. Int J Mol Sci 2021;22(24):136–45. doi: 10.3390/ijms222413659
  2. Khan A.W., Farooq M., Haseeb M., Choi S. Role of plantderived active constituents in cancer treatment and their mechanisms of action. Cells 2022;11(8):1326. doi: 10.3390/cells11081326
  3. Bocharova O.A., Karpova R.V., Bocharov E.V. et al. Research of new phytoadaptogens and possibilitirs of herbal formulas application. Rossijskij bioterapevticeskij zurnal = Russian Journal of Biotherapy 2020;19(4):35–44. (In Russ.). doi: 10.17650/1726-9784-2020-19-4-35-44
  4. Panossian A. Challenges in phytotherapy research. Front Pharmacol 2023;14:1199516. doi: 10.3389/fphar.2023.1199516
  5. Zhang Y., Rumgay H., Li M. et al. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health 2023;13:04109. doi: 10.7189/jogh.13.04109
  6. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Kaprin A.D., Starinsky V.V., Shakhzadova A.O., eds. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
  7. Han J., Gu X., Li Y., Wu Q. Mechanisms of BCG in the treatment of bladder cancer – current understanding and prospect. Biomed Pharmacother 2020;129:110393. doi: 10.1016/j.biopha.2020.110393
  8. Larsen E.S., Joensen U.N., Poulsen A.M. et al. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. APMIS 2020;128(2):92–103. doi: 10.1111/apm.13011
  9. Lidagoster S., Ben-David R., De Leon B., Sfakianos J.P. BCG and alternative therapies to BCG therapy for non-muscleinvasive bladder cancer. Curr Oncol 2024;31(2):1063–78. doi: 10.3390/curroncol31020079
  10. Bocharova O.A., Karpova R.V., Golubeva V.A. et al. Evaluation of the antimetastatic and immunomodulating activity of the preparation Phytomix-40 in the in vivo experiment. Bulleten eksperimentalnoy biologii y meditsiny = Bulletin of Experimental Biology and Medicine 1999;128(10):403–7. (In Russ.).
  11. Bocharova O.A., Matveev V.B., Baryshnikova M.A. et al. Pharmaceutical composition showing cytotoxic action against human bladder cancer cells. Russian Federation Patent No.2693378 of 02.07.2019. Bulletin No. 19. (In Russ.).
  12. Bocharova O.A., Kazeev I.V., Shevchenko V.E. et al. Methodological approaches to standardization of phytoadaptogens. Methodological guidelines. Moscow, 2022. 98 p. (In Russ.). doi: 10.18720/SPBPU/2/z22-28
  13. Hao F., Deng X., Yu X., Wang W. et al. Taraxacum: a review of ethnopharmacology, phytochemistry and pharmacological activity. Am J Chin Med 2024;52(1):183–215. doi: 10.1142/S0192415X24500083
  14. Lahlou A., Lyashenko S., Chileh-Chelh T. et al. Fatty acid profiling in the genus Pinus in relation to its chemotaxonomy and nutritional or pharmaceutical properties. Phytochemistry 2023;206:113517. doi: 10.1016/j.phytochem.2022.113517
  15. Gonçalves A.C., Flores-Félix J.D., Coutinho P. et al. Zimbro (Juniperus communis L.) as a promising source of bioactive compounds and biomedical activities: a review on recent trends. Int J Mol Sci 2022;23(6):3197. doi: 10.3390/ijms23063197
  16. Ak G., Gevrenova R., Sinan K.I. et al. Tanacetum vulgare L. (Tansy) as an effective bioresource with promising pharmacological effects from natural arsenal. Food Chem Toxicol 2021;153:112268. doi: 10.1016/j.fct.2021.112268
  17. Michels B., Franke K., Weiglein A. et al. Rewarding compounds identified from the medicinal plant Rhodiola rosea. J Exp Biol 2020;223(Pt 16):jeb223982. doi: 10.1242/jeb.223982
  18. Sheichenko O.P., Bocharova O.A., Krapivkin B.A. et al. Chemical composition determination of volatile compounds of the phytoadaptogen Fitomix-40 by chromato-massspectrometry. Voprosy biologicheskoy, meditsinskoy i farmatsevticheskoy khimii = Problems of biological, medical and pharmaceutical chemistry 2008;5:18–28. (In Russ.).
  19. Groot A.C., Schmidt E. Essential Oils. Part III: Chemical composition. Dermatitis 2016;27(4):161–9. doi: 10.1097/DER.0000000000000193
  20. Sut S., Maccari E., Zengin G. et al. “Smart extraction chain” with green solvents: extraction of bioactive compounds from Picea abies bark waste for pharmaceutical, nutraceutical and cosmetic uses. Molecules 2022;27(19):6719. doi: 10.3390/molecules27196719
  21. Câmara J.S., Perestrelo R., Ferreira R. et al. Terpenoids: a plethora of bioactive compounds with several health functions and industrial applications – a comprehensive overview. Molecules 2024;29(16):3861. doi: 10.3390/molecules29163861

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.